NCT-05753722

An Open-Label Phase 1 Dose-Escalation and Expansion Study Investigating the Safety,Pharmacokinetics, Pharmacodynamics, and Activity of PRTH-101 Alone or in Combination with Pembrolizumab in Adults with Locally Advanced or Metastatic Solid Tumors

This is an open-label Phase 1 study that tests the safety, how the body processes the drug, its effects, and how well it works. The study is investigating PRTH-101, both alone and in combination with Pembrolizumab, in adults with locally advanced or metastatic solid tumors (cancers that have spread or are hard to treat). The study will first test different doses of PRTH-101 to find the right amount, and then expand to include more patients to better understand how the drug works. PRTH-101 is being studied for its potential to help the immune system recognize and attack cancer by targeting specific proteins on tumor cells. Pembrolizumab is an immune checkpoint inhibitor that boosts the immune system by blocking a protein on cancer cells that helps them hide from immune detection, allowing the immune system to more effectively target and destroy the cancer cells.

Phase 1: First step in testing a new medicine in people, and tests if treatment is safe, determines the right dose, and checks for any side effects.

open-label: Patients know which treatments are being given to them

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT05753722

Clinical Trial Site: Einstein

To see all available clinical trials click here.